Patients who receive GLP-1 receptor agonist semaglutide (Ozempic; Novo Nordisk) may have an increased risk of developing nonarthritic anterior ischemic optic neuropathy (NAION), according to a...
ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — What to prioritize first in managing early diabetes? That was the question debated on an expert panel at the American Diabetes Association (ADA)...
MONTREAL —Tirzepatide (Mounjaro, Eli Lilly), the dual gastric inhibitory polypeptide–glucagon-like peptide 1 (GIP–GLP-1) receptor agonist that has shown significant benefits in diabetes and obesity, may also...
ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73%...
ORLANDO, FL — The diabetes and weight loss drug tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity) was so effective at reducing sleep disruptions in...
TOPLINE: Bariatric metabolic surgery (BMS) offers a survival advantage over glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in adults with obesity and diabetes for ≤ 10...
TOPLINE: Semaglutide does not appear to increase the risk for postoperative pneumonia in diabetic patients undergoing elective surgery, a new study found. METHODOLOGY: Researchers conducted a...